Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc

Bullboard Posts

Post by lonc17on Oct 12, 2005 12:18am

617 Views

Post# 9687900

accumulation?

1/3 of the trading days this year showing volume over 100,000 (oncy, nasdaq) have happened after the sept 27 US Systemic announcement. I have seen this happen with a number of companies, where the volume takes a sustained turn up. The share price will follow as accumulation by institions continues. I'm thinking $6.50 US within three weeks on the build-up to de Bono's poster. With respect to NCI, ONC could be saying 'why bother with chemo combo' as they see the results flow in from Marsden... perhaps the lack of news on this front could be taken as a postive.

Bullboard Posts

FE Battery Metals begins 2024 winter drill program